"Product Profiles: Melanoma - Novel Combination Therapies Will Increase Competition for Marketed Drugs" - New Market Report
The melanoma market has seen an increase in developer attention following recent breakthroughs. The identification of the role of BRAF mutations has revolutionized the treatment of melanoma, but with drug resistance a problem there is an opportunity for developers to move into this market. Novel combination therapies and immunotherapies are now poised to compete with the current marketed drugs.
View full press release